SANOFI-AVENTIS (EPA:SAN)

PRESS RELEASE

published on 05/30/2024 at 15:01, 1 year 9 months ago

Press Release: Sanofi completes acquisition of Inhibrx, Inc.
Sanofi completes acquisition of Inhibrx, Inc., adding SAR447537 to rare disease pipeline. Former Inhibrx shareholders receive $30.00 per share in cash and one contingent value right. Inhibrx Biosciences begins trading on NASDAQ as INXB

Acquisition Nasdaq Sanofi Inhibrx SAR447537
BRIEF

published on 05/27/2024 at 07:05, 1 year 9 months ago

FDA Grants Priority Review to Sarclisa for Treatment of Multiple Myeloma

FDA Sanofi Multiple Myeloma Sarclisa Chemotherapy
BRIEF

published on 05/21/2024 at 07:35, 1 year 9 months ago

Sanofi, Formation Bio, and OpenAI Announce AI Collaboration

Collaboration AI Drug Development Sanofi OpenAI Formation Bio
PRESS RELEASE

published on 05/21/2024 at 07:30, 1 year 9 months ago

Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration
Sanofi, Formation Bio, and OpenAI collaborate to accelerate drug development with AI-powered software. The partnership aims to bring new medicines more efficiently

Collaboration Drug Development Sanofi OpenAI Formation Bio
BRIEF

published on 05/20/2024 at 22:59, 1 year 9 months ago

Sanofi: April 2024 Voting Rights and Shares Information

Voting Rights Shares Financial Disclosure April 2024 Sanofi
PRESS RELEASE

published on 05/20/2024 at 22:54, 1 year 9 months ago

Sanofi: Information concerning the total number of voting rights and shares - April 2024
Sanofi provides total number of issued shares and voting rights as per French Commercial Code and AMF regulations for April 30, 2024

Share Capital Voting Rights French Commercial Code AMF Regulations Sanofi
BRIEF

published on 05/20/2024 at 20:20, 1 year 9 months ago

Dupixent® Reduces COPD Exacerbations in Phase III Study

FDA Clinical Study Inflammation COPD Dupixent
PRESS RELEASE

published on 05/20/2024 at 20:15, 1 year 9 months ago

Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM
Late-breaking data from NOTUS confirm Dupixent's effectiveness in reducing COPD exacerbations and improving lung function, presented at ATS and published in NEJM

COPD Dupixent NOTUS Lung Function Exacerbations
BRIEF

published on 05/10/2024 at 08:05, 1 year 9 months ago

Sanofi and Novavax Form Strategic Alliance to Enhance Vaccine Accessibility

COVID-19 Vaccine Vaccine Development Sanofi Novavax Flu Vaccine
PRESS RELEASE

published on 05/10/2024 at 08:00, 1 year 9 months ago

Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines
Sanofi and Novavax sign co-exclusive licensing agreement to co-commercialize COVID-19 vaccine & develop flu-COVID-19 combo vaccines. Agreement enhances patient access & protection. Details in press release

COVID-19 Vaccine Licensing Agreement Sanofi Novavax Flu-COVID-19

Published on 03/05/2026 at 17:55, 1 hour 8 minutes ago

ACCESS Newswire to Host Fourth Quarter and Year End Earnings Conference Call on March 19, 2026
Published on 03/05/2026 at 14:00, 5 hours 3 minutes ago

EQ Inc. Secures Strategic Partnership with Global Card Network to Expand Integrated Rewards Across Canada
Published on 03/05/2026 at 14:00, 5 hours 3 minutes ago

GameSquare's Stream Hatchet Publishes 2025 YouTube Gaming Trends Report
Published on 03/05/2026 at 14:00, 5 hours 3 minutes ago

Horizon Aircraft's Unique VTOL Delivers Up to 75% Lower Operating Costs Than Helicopters
Published on 03/05/2026 at 13:40, 5 hours 23 minutes ago

Lobe Sciences Ltd. Announces Presence in Miami During the Jefferies and Leerink Healthcare Conferences

View all ACCESSWIRE

Published on 03/05/2026 at 18:48, 15 minutes ago

POS-Transaction in Own Shares
Published on 03/05/2026 at 18:17, 46 minutes ago

Cairn Homes Plc: Holding(s) in Company
Published on 03/05/2026 at 17:57, 1 hour 6 minutes ago

EQS-Adhoc: Delivery Hero SE may redeem convertible bonds in H1 2026 using proceeds from a USD 1.5bn increase of its term loans subject to certain conditions
Published on 03/05/2026 at 17:48, 1 hour 14 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 03/05/2026 at 17:45, 1 hour 18 minutes ago

Swiss Prime Site announces the conversion price of its CHF 350 million green convertible bonds due 2032 and the outcome of the incentivized conversion invitation

View all EQS

Published on 03/05/2026 at 18:40, 23 minutes ago

2025 Full-year results FREY: a pan-European platform already creating value
Published on 03/05/2026 at 18:34, 28 minutes ago

Mersen: Number of shares and voting rights as of February 28, 2026
Published on 03/05/2026 at 17:45, 1 hour 18 minutes ago

February 2026
Published on 03/05/2026 at 17:45, 1 hour 18 minutes ago

Cie du Bois Sauvage : Results 2025
Published on 03/05/2026 at 13:20, 5 hours 42 minutes ago

Voting rights

View all LES ECHOS COMFI WIRE

News